How to Sell Peptides

what may a supplement legally claim here?

The honest answer is: often nothing, because the product isn't a supplement in the first place. 21 U.S.C. 321(ff)(1) defines a dietary supplement with a closed list — vitamins, minerals, herbs, amino acids and similar dietary substances — and food-derived peptides like hydrolyzed collagen and whey protein hydrolysates fit that list. Synthetic research peptides such as BPC-157, TB-500 or epitalon don't fit that list. DSHEA's drug-preclusion clause at 321(ff)(3)(B) closes the door further: an article already under investigation as a new drug is excluded from the supplement category unless it was marketed as food or a supplement first.

That's why the label "research use only" doesn't do what sellers hope. FDA's March 2026 warning letter to Gram Peptides quoted the company's own disclaimer: "not intended for human consumption, medical use, or veterinary use." The agency then found the opposite: "evidence obtained from your website establishes that your products are intended to be drugs for human use." We read that letter as the clearest single document in this niche: it shows exactly which website elements FDA treated as evidence, mechanism-of-action copy and weight-loss claims on the product pages themselves. Which side of that line a specific peptide falls on is a product-by-product question; see is selling research peptides legal for the current analysis.

Food-derived peptides keep the DSHEA safe harbor; synthetic ones lose it entirely. Hydrolyzed collagen and whey hydrolysates can carry a structure/function claim like "supports skin elasticity" with the standard disclaimer required under 21 CFR 101.93(c) — the same ground we cover on our how to sell nutraceuticals page. If you're selling that side, the disclaimer rule applies to your label exactly as it does to any other supplement. Synthetic research peptides get no such disclaimer, because there's no safe harbor to attach one to.

who is the buyer, really?

Two buyers dominate this niche, and they rarely overlap. The first is priced out of an FDA-approved GLP-1 drug and goes looking for a compounded or telehealth alternative to Ozempic, Wegovy, Mounjaro or Zepbound. The second is a biohacker or gym-focused buyer chasing recovery peptides like BPC-157 or TB-500 for an injury or a training goal. FDA's warning-letter targets and the FTC's substantiation guidance point the same direction: both buyers are searching for a cheaper or unregulated substitute for a drug they already know is real.

For the weight-loss buyer, the purchase increasingly runs through a clinic rather than a website cart, which changes who's liable when the product isn't what it claimed. Alabama's medical board warned in May 2026 that "under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient." The state's attorney general sued a Cullman IV clinic months earlier for injecting patients with material labeled for laboratory research only, and won a permanent closure and about $24,000 in penalties. The buyer there wasn't reading a label; a person in scrubs told them the shot was pharmaceutical-grade.

That clinic channel is also getting harder to run legally. Oregon's SB 951, in effect for new arrangements since January 2026, bars management companies from controlling a clinic's medical decisions, and California's SB 351 does the same for private-equity-backed practices starting the same year. Selling into a med-spa network now means the buyer's own clinic may be non-compliant before your product ever enters the room.

what does the enforcement record show?

The enforcement record shows two tracks running at once, not isolated cases. FDA's warning-letter database carries 139 letters mentioning semaglutide and 108 mentioning tirzepatide issued between 2024 and 2026, most from coordinated telehealth sweeps rather than one-off investigations, while state attorneys general are filing separately against the clinics and distributors FDA doesn't reach directly.

None of this required a jury trial to bite. The FTC's April 2023 Notices of Penalty Offenses went to roughly 670 companies selling OTC drugs, supplements and functional foods, warning that a future violation could draw civil penalties instead of a consent order. That mechanism applies just as well to a compounded-peptide seller as to any other supplement brand it named.

what does the product actually cost to make?

What it costs depends on which side of the DSHEA line you're on.

A food-derived peptide product — a collagen powder or a whey-hydrolysate capsule — runs through an ordinary supplement supply chain. SMP Nutra prices stock formulas at $4 to $20 per unit and custom formulations at $5 to $30 per unit, at a standard run of 2,500 to 5,000 bottles. A four-metal heavy-metals COA alone runs $164 to $334 per sample, depending on whether it's bundled or ordered a-la-carte. Add 20 to 40% for one-time formulation, stability testing and label tooling, and budget a first production run for one SKU in the low five figures before a single unit ships.

Synthetic injectable peptides don't run through that chain at all. There's no retail MOQ, bottling or COA pricing to quote for this side. The lawful version of the product moves through a 503A or 503B compounding pharmacy under prescription, not a supplement contract manufacturer — see our best peptides supplier page for how that sourcing question gets answered. FDA's May 2026 bulk-substances list holds only six drugs in the compounding-eligible Category 2, and BPC-157 isn't one of them; it was withdrawn from consideration entirely as of April 22, 2026, a procedural move FDA is careful to distinguish from a safety finding. We didn't find a published consumer-facing cost figure for this side of the market, and we're not going to fabricate one.

what does the competition already run?

The current playbook runs on LegitScript-gated telehealth funnels, "research use only" labeling and outright cloaking to survive ad review, and all three are getting harder to sustain. On Meta, promoting a prescription drug requires the platform's own authorization. Eligible advertisers are limited to online pharmacies, telehealth providers and pharmaceutical manufacturers holding active LegitScript certification, with targeting capped to the United States, Canada and New Zealand — a gate that applies to you regardless of how the ad copy reads.

Google runs a parallel gate: online pharmacies need LegitScript or NABP accreditation, telemedicine providers need LegitScript certification, and Google's reference list of restricted prescription terms names semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, Mounjaro and Zepbound by name. Neither certification requirement is something a landing page talks its way around. Sellers who can't get certified fall back on cloaking and "research use only" framing instead. Meta has begun suing over exactly that. Its February 2026 complaint against a Vietnam-based advertiser described cloaking as a page that "displays one version of its content to our ad review system, but shows different content to real users."

TikTok treats supplements as restricted rather than banned, but requires proof of local regulatory approval plus an 18+ age gate, and bans before/after imagery for supplements outright in a named set of markets. We could not verify whether Meta's unpublished health-and-wellness advertiser restrictions name peptide sellers as a category; Meta hasn't published that list, and confirming it would take an actual account-restriction notice, not another policy page.

where does the claim ceiling bite hardest?

The ceiling here isn't a claims list — it's the entire safe harbor, and for synthetic research peptides it doesn't exist. Where a nutraceutical brand can make a lawful structure/function claim with the right disclaimer, a synthetic peptide seller has no such claim available, because the product was never a supplement to begin with. Anything that shows human-use intent converts it into an unapproved new drug under FD&C Act sections 201(g) and 201(p) — see which peptides are banned by FDA for the current roster your next campaign needs to clear.

For compounded GLP-1s specifically, the ceiling has been dropping in real time. FDA ended its enforcement-discretion wind-down for tirzepatide in February 2025 and for semaglutide in April and May 2025. Its April 2026 proposal would go further, excluding semaglutide, tirzepatide and liraglutide from the 503B bulk-substances list. FDA Commissioner Marty Makary put the "same as" claim itself off-limits, stating companies "cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA." The personalized-dosing exception some compounders lean on is narrow by statute: it requires a documented, patient-specific "significant difference" determined by the prescriber, not a menu of dosing tiers offered to everyone.

Retatrutide and cagrilintide sit below even that floor. FDA states plainly that "retatrutide and cagrilintide cannot be used in compounding under federal law" because neither is a component of an FDA-approved drug, a point the agency has made directly to telehealth companies, API distributors and outsourcing facilities alike. Selling either one for human use, at any dose, on any label, is selling an unapproved drug.

what makes this niche harder than it looks?

A "research use only" label, bundled reconstitution supplies and a mechanism-of-action study citation are not separate small risks. FDA treats each one as evidence of the same thing — intended human use — and they stack rather than cancel out. In the Gram Peptides letter, selling bacteriostatic water alongside peptides requiring reconstitution was itself treated as evidence the water was meant "to be used in combination for injection."

The rules themselves are also still moving, which matters for anyone reading this months from now. FDA's advisory committee voted in July 2026 to recommend adding BPC-157 and five other peptides to the compounding-eligible list. We checked FDA's own bulk-substances list against that vote and found it unchanged — the recommendation hadn't been adopted as of this writing. That's consistent with what the vote actually is: as Mintz's analysis put it, "an advisory committee vote is not an agency action," and the recommendations "are not binding on FDA." The semaglutide shortage-delisting fight is still in front of the Fifth Circuit, and a prior tirzepatide shortage determination was itself remanded once in litigation before FDA settled the question in December 2024.

Check the compounding list again before you build a campaign on it.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Three Supplement Offers Dome Keeper: The Practical Version, Describe Medicare Supplement Who Offers It, How Much Does It Cost to Private Label Supplements?, Health & Fitness Affiliate Marketing: Nutra Vertical Guide for Sellers and Affiliates, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.